Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series: World’s leading Event Organizer



Dr Ayad Abdul-Ahad, MD, PhD, FRCPath, is a physician specialised in Oncology, Immunology and Haematology. He trained in various teaching hospitals in the United Kingdom. He has spent the last 25 years in drug Development and Medical Affairs. Ayad has built and led teams across the Pharmaceutical and Biotechnology industries in the US and Europe that managed the clinical development and medical affairs for several drugs in Oncology, Neurology, Pain, and  Immunology


More clinically relevant outcome measures are greatly needed to allow physicians, health authorities, Healthcare providers and patients to make robust therapeutic choices. 21st Century therapeutic decisions need to into account many factors such; increasing complexity of drugs, personalised medicine, and the demands of Healthcare providers for proof of cost effectiveness, the impact on the quality of life, & patient reported outcomes. Rapid scientific advances are leading to the development of new drugs that are usually more expensive, thus increasing the pressure on budgets and demands for more evidence based medicine. Hence, the increasing the need for more clinically relevant outcome measures to assist in choosing the right drugs. These outcome measure should take into account; the impact on the Natural History of Cancer and other conditions, & the burden of drugs on patient safety and quality of life. Clinical trials data are the basis for therapeutic decisions. However, some outcome measures do not provide the robust basis to make these decisions In Cancer, time to clinical progression, MRI progression, surrogate marker progression are analysed separately. No collective impact on the Natural History of Cancer is measured. The data collected after progression, is not usually presented. Safety data are reported as an absolute list or summary with the number of patients with a specific AE. No identification patients who experience more than one AE contemporaneously, consecutively or the combination of incidence and severity and their impact on patients. I will present a new outcome measure utilising collected data that that aims to help these needs.